Compare ADMA Biologics Inc (ADMA) vs Core and Main Inc (CNM) Price & Performance

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Core & Main (CNM) trades at $45.98, up 2.34% with recent earnings beats driving positive momentum. The stock shows bearish technical signals with resistance at $46-$48, while fundamentals remain solid with 23.73% ROE and consistent revenue growth. Recent Q1 2026 results exceeded expectations at $0.72 EPS versus $0.70 estimate, supported by strong municipal demand and margin expansion initiatives. The company maintains stable cash flow generation with $655M operating cash flow projected for 2026.

CNM presents a mixed outlook with strong fundamentals offset by technical weakness. The bullish analyst consensus (57% buy ratings) and improving debt profile support upside potential, but near-term price pressure from bearish technical indicators requires caution. Key risks include residential market softness and industry supply chain challenges, though the company's reaffirmed FY26 guidance of $7.8-7.9B revenue provides stability.